Overview

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Status:
Terminated

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of ABT-957 in subjects with mild to moderate Alzheimer's disease.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Cholinesterase Inhibitors